Amarin (AMRN) Given a $10.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $10.00 price target on Amarin (NASDAQ:AMRN) in a report released on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the stock. ValuEngine cut shares of Amarin from a hold rating to a sell rating in a research report on Thursday, November 16th. Jefferies Group restated a buy rating on shares of Amarin in a research report on Wednesday, October 11th. HC Wainwright restated a buy rating and issued a $10.00 price objective on shares of Amarin in a research report on Thursday, November 2nd. Zacks Investment Research cut shares of Amarin from a buy rating to a hold rating in a research report on Friday, November 3rd. Finally, BidaskClub cut shares of Amarin from a sell rating to a strong sell rating in a research report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Amarin has an average rating of Hold and a consensus price target of $7.75.

Amarin (AMRN) opened at $4.09 on Tuesday. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32. The firm has a market cap of $1,072.68, a P/E ratio of -15.15 and a beta of 0.66. Amarin has a 52-week low of $2.81 and a 52-week high of $4.47.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million during the quarter, compared to the consensus estimate of $45.85 million. The firm’s revenue for the quarter was up 45.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.08) earnings per share. analysts anticipate that Amarin will post -0.22 EPS for the current year.

In other news, insider Steven B. Ketchum sold 63,479 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $3.48, for a total value of $220,906.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John F. Thero bought 10,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was purchased at an average price of $3.24 per share, for a total transaction of $32,400.00. The disclosure for this purchase can be found here. 3.72% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. Westside Investment Management Inc. grew its holdings in shares of Amarin by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 300 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Amarin by 15.2% in the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 5,000 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Amarin in the third quarter worth approximately $226,000. Stevens Capital Management LP bought a new position in shares of Amarin in the third quarter worth approximately $229,000. Finally, TD Asset Management Inc. bought a new position in shares of Amarin in the third quarter worth approximately $285,000. Hedge funds and other institutional investors own 40.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Amarin (AMRN) Given a $10.00 Price Target by Cantor Fitzgerald Analysts” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/23/amarin-amrn-given-a-10-00-price-target-by-cantor-fitzgerald-analysts.html.

About Amarin

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit